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Edited by Richard MaraisAbstract We demonstrate here that neuronal nitric-oxide
synthase (nNOS) is phosphorylated and inhibited by a consti-
tutively active form of Ca2þ/calmodulin (CaM)-dependent pro-
tein kinase I (CaM-K I1-293). Substitution of Ser741 to Ala in
nNOS blocked the phosphorylation and the inhibitory eﬀect.
Mimicking phosphorylation at Ser741 by Ser to Asp mutation
resulted in decreased binding of and activation by CaM, since the
mutation was within the CaM-binding domain. CaM-K I1-293
gave phosphorylation of nNOS at Ser741 in transfected cells,
resulting in 60–70% inhibition of nNOS activity. Wild-type
CaM-K I also did phosphorylate nNOS at Ser741 in transfected
cells, but either CaM-K II or CaM-K IV did not. These results
raise the possibility of a novel cross-talk between nNOS and
CaM-K I through the phosphorylation of Ser741 on nNOS.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ca2þ/calmodulin (CaM)-dependent kinase I (CaM-K I) is
highly expressed in the brain and moderately in peripheral
tissues [1]. It can phosphorylate a number of in vitro sub-
strates, including synapsin 1 and 2 [2], cyclic AMP-response
element binding protein (CREB) [3,4], and cystic ﬁbrosis
transmembrane conductance regulator (CFTR) [5]. But its
physiological substrates are not clear. Neuronal nitric-oxide
synthase (nNOS) is also a Ca2þ/CaM-dependent enzyme,
which catalyzes the oxidation of L-arginine to generate nitric-
oxide (NO) and L-citrulline [6]. It has been established that
nNOS is phosphorylated by CaM-K II [7,8], leading to a re-
duction of nNOS activity through the phosphorylation at
Ser847 of the enzyme [9,10]. It was recently shown that the
Ser847 phosphorylation of nNOS occurs physiologically in rat* Corresponding author. Fax: +81-87-891-2096.
E-mail address: yasuwata@kms.ac.jp (Y. Watanabe).
Abbreviations: CaM, calmodulin; nNOS, neuronal nitric-oxide syn-
thase; CaM-K I, II, and IV, calcium/calmodulin-dependent protein
kinases I, II, and IV; CaM-KK, calcium/calmodulin-dependent protein
kinase kinase; PP2A, protein phosphatase 2A
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transfected cells, CaM-K II but neither CaM-K I nor CaM-K
IV can phosphorylate nNOS on Ser847 [14]. In the present
study, we demonstrate that phosphorylation of nNOS at
Ser741, attenuating its enzyme activity, is catalyzed by CaM-K
I, while CaM-K II and CaM-K IV are not involved.2. Materials and methods
2.1. Materials
The cDNA for rat brain nNOS was a generous gift from Dr. Solo-
mon H. Snyder (Johns Hopkins University School of Medicine, Bal-
timore, MD) [6]. A mouse anti-CaM-K IIa monoclonal antibody
(mAb) was obtained from Oncogene. A mouse anti-CaM-K IV mAb
was obtained from Transduction Laboratories, Inc. The mouse anti-
nNOS mAb was obtained from Sigma. protein phosphatase 2A
(PP2A) was purchased from Upstate Biotechnology. The rabbit anti-
CaM-K I polyclonal antibody (pAb) was provided by Dr. Angus C.
Nairn (Yale University School of Medicine, New Haven, CT) [15].
2.2. Anti-phosphopeptide-speciﬁc antibodies
Rabbit pAb raised against phosphopeptide based on the amino acid
sequence of rat nNOS CEAVKF(Sp)AKLMG (NP741) was puriﬁed
by tandem column chromatography using phosphopeptide and de-
phosphopeptide columns. NP847 pAb, recognizing phosphorylation at
Ser847 on nNOS, was prepared as described previously [9].
2.3. Plasmid construction
PCWnNOS and pVL1393nNOS, the plasmids for the expression of
nNOS in E. coli and Sf9 cells, respectively, were constructed as de-
scribed before [16,17]. The pME18s-nNOS was generated as described
previously [10]. CaM-K Ia, CaM-K IIa, CaM-K IV, and CaM kinase
kinase (CaM-KK) were cloned from a rat brain cDNA library, then
the cDNAs were cloned into pME18s. The constitutively active con-
struct, pME18s-CaM-KK1-434, was generated as described previously
[18]. CaM-kinase Ia1-293 and HA-CaM-K IV were subcloned into
pME18s. The mutants CaM-K Ia1-293, K49A, nNOS S741A, S741D,
and S847A, which are, respectively, substituted Lys49 by Ala, Ser741 by
Ala, Ser741 by Asp, and Ser847 by Ala, were subcloned into pME18s
and pCW. The nucleotide sequences of each mutant were conﬁrmed.
2.4. In vitro activation of CaM-K Ia1-293 and CaM-K IV and
phosphorylation of nNOS
CaM-K I1-293 is phosphorylated and activated by CaM-KK
through Thr177 phosphorylation in both the presence and absence of
Ca2þ/CaM [19]. We employed constitutively active form of CaM-KK
(CaM-KK1-434) to activate CaM-K I1-293 in the absence of Ca2þ/
CaM. Recombinant GST-CaM-kinase Ia1-293 [20] (5 lM) was
preincubated with recombinant CaM-KK1-434 (190 nM) at 30 C in
50 mM HEPES (pH 7.5), 5 mM MgCl2, 1 mM DTT, 1 mM EGTA,
400 lg/ml bovine serum albumin, and 1 mM ATP. The reaction wasblished by Elsevier B.V. All rights reserved.
Fig. 1. Inhibition of nNOS activity by a constitutively active form of
CaM-K I in vitro. Wild-type nNOS (1 lM) expressed in Sf9 cells was
incubated with (CaM-K I1-293/CaM-KK1-434) or without (Control)
an activated GST/CaM-K I1-293 (200 nM), as described under Section
2, for 30 min at 30 C in the absence of Ca2þ/CaM with 1 mM ATP.
Equivalent amounts (140 nM) of nNOS were treated either with heat-
inactivated (10 min at 60 C: boiled lysates) or non-heat inactivated
(lysates) brain extracts (24 lg of protein) for 10 min at 30 C in the
presence or absence of 10 lM okadaic acid (OA). Then the NOS en-
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C. Recombinant CaM-K IV (3.8 lM) was preincubated with re-
combinant CaM-KK (168 nM) at 30 C in 50 mMHEPES (pH 7.5), 10
mMMgCl2, 1 mM DTT, 1.2 mM CaCl2, 1 lMCaM, and 1 mM ATP.
The reaction was terminated at 30 min by a 10-fold dilution at 4 C
with 50 mM HEPES (pH 7.5), 5 mM EDTA, 2 mg/ml bovine serum
albumin, and 10% glycerol. The phosphorylation reaction for nNOS
was performed for 30 min at 30 C in 10 ll of 40 mMHEPES (pH 7.0),
10 mM MgCl2, 0.4 mM DTT, 1 mM EGTA, 1 mM ATP, 400 lg/ml
bovine serum albumin, and 1 lM nNOS in the presence of 100–200
nM of activated CaM-kinases with or without [c-32P]ATP. The lysates
from rat brain were used as a source of protein phosphatase to de-
phosphorylate the phosphorylated nNOS. Brieﬂy, rat brain was soni-
cated with 4 volume of 50 mM HEPES (pH 7.4), 0.1% Triton X-100, 2
mM EGTA, 2 mM EDTA, 10 lg/ml leupeptin, 1 lg/ml pepstatin A,
and 1 lg/ml aprotinin. After centrifugation at 15 000 g for 15 min,
the supernatant was used as a source of protein phosphatase.
2.5. Assay of nNOS activity
NOS activity was determined by measuring the conversion of
L-[3H]arginine to L-[3H]citrulline as described previously [16,21] in 20
ll of 40 mM Tris–HCl buﬀer, pH 7.5, containing 100 nM nNOS, 1 lM
CaM, 100 lM L-[3H]arginine, 0.1 mM NADPH, 20 lM BH4, 4 lM
FAD and 4 lM FMN.
2.6. Cell culture, transfection, and stimulation
HEK-293 cells in 10-cm dishes were transfected with pME18s plas-
mids containing wild-type nNOS (5 lg) with each combination con-
taining CaM-K Ia (5 lg)/CaM-KK1-434 (1 lg), CaM-K IIa (5 lg),
HA-CaM-K IV (5 lg)/CaM-KK1-434 (1 lg) using LipofectAMINE
Plus method (Life Technologies, Inc.). After 36–48 h incubation, the
cells were incubated for 60 min in serum-free medium. The cells were
then stimulated with 10 lM A23187 (Sigma) for 3.5 min. For the de-
termination of constitutively active form of CaM-K I that phospho-
rylates Ser741 of nNOS, the cells were transfected with pME18s
plasmid containing wild-type nNOS or mutant nNOS (S741A) (5 lg),
CaM-KK1-434 (1 lg), and CaM-K Ia1-293 or inactive CaM-K Ia1-
293 (K49A) (5 lg).zyme activity, negligible in the lysates itself, was assayed by measuring
the conversion of L-[3H]arginine to L-[3H]citrulline. The inset shows
the data for an application of 100 nM PP2A instead of the extracts
from rat brain. The means S.E. of three experiments are shown.3. Results and discussion
3.1. Eﬀect of the phosphorylation of nNOS by a constitutively
active form of CaM-K I on NOS enzyme activity
To assess the activity of phosphorylated nNOS by activated
CaM-K I1-293, the conversion of [3H]arginine to citrulline was
measured. Phosphorylation of nNOS by activated CaM-K I1-
293 decreased NOS activity to 10–15% (Fig. 1). Whether this
attenuation was reversed by treatment of protein phosphatase,
we used the extracts from rat brain as a source. The incubation
of the phosphorylated nNOS with the extracts reversed the
attenuation completely. The inclusion of 1 lM okadaic acid
largely blocked the reversal eﬀect by the extracts. The extracts
could contain other factors that stimulate nNOS activity even
in the presence of phosphorylation at Ser741. Therefore, we
examined whether treatment with PP2A resulted in the same
eﬀect with that of the extracts. As shown in Fig. 1, inset, the
decrease in NOS activity induced by activated CaM-K I1-293
was reversed by treatment with PP2A.
3.2. Identiﬁcation of CaM-K I1-293-dependent phosphorylation
sites in nNOS
The CaM-binding ability of phosphorylated nNOS by acti-
vated CaM-K I1-293 was signiﬁcantly blocked as assessed by
the CaM overlay technique (Fig. 3A). Therefore, we made a
single mutant by introducing Ala residues in place of Ser741
(S741A), since Ser741 was within the CaM-binding domain of
nNOS. Wild-type and the mutant were expressed using the E.
coli system and puriﬁed on 20-50-ADP-agarose as described inSection 2. The recombinant nNOSs were at least 90% pure as
analyzed by densitometric scanning and gave a major band at
160 kDa on SDS–PAGE with Coomassie brilliant blue (CBB)
staining (Fig. 2A). Phosphorylation of the mutant by activated
CaM-K I1-293 was decreased as compared with that of the
wild-type enzyme (Fig. 2B). The results suggest that activated
CaM-K I1-293 may also phosphorylate nNOS at diﬀerent sites
as well, since the mutation of Ser741 did not fully block the
phosphorylation of nNOS by the kinase. Next, we examined
the ability of Ser741 residue phosphorylation to aﬀect NOS
activity. Mutation of Ser741 to Ala abolished CaM-K I1-293-
dependent attenuation of NOS activity (Fig. 3B). Mutation of
Ser741 into aspartic acid (S741D), to substitute for the negative
charge aﬀorded by the addition of phosphatase, mimicked the
inhibition state by CaM-K I1-293 (Fig. 3B). The CaM-binding
of phosphorylated nNOS or mutant S741D was almost com-
pletely blocked as assessed by the CaM overlay technique
(Fig. 3A). Mutant S741A exhibited similar CaM binding
ability as the wild-type enzyme and this was not signiﬁcantly
aﬀected by the CaM-K I1-293-dependent phosphorylation of
the mutant (Fig. 3A).
3.3. Phosphorylation of nNOS at Ser741 by CaM-K I1-293 in
transfected cells
Since CaM-K I1-293-induced Ser741 phosphorylation in
nNOS is functionally important for NOS activity, this residue
Fig. 3. Characterization of charged insertion mutant of nNOS. (A)
Equal amounts (0.5 lg) of wild-type (WT) and the indicated mutants
nNOSs in E. coli were incubated with buﬀer alone ()) or activated
GST/CaM-K I1-293 for 30 min (+) at 30 C in the absence of Ca2þ/
CaM with 1 mM ATP. The reaction was stopped by addition of
sample buﬀer. Then, the samples were analyzed by 7.5% SDS–PAGE,
transferred onto PVDF membranes, and analyzed by reaction with
biotinylated CaM overlay (lower panel). The same membranes were
then stained with Amido Black (upper panel). (B) Wild-type and the
indicated mutants nNOSs in E. coli were incubated with or without an
activated GST/CaM-K I1-293 as in Fig. 1. Equivalent amounts (100
nM) of unphosphorylated (opened column) and phosphorylated (closed
column) nNOSs were used for the NOS enzyme activity assay as in Fig.
1. The meansS.E. of three experiments are shown.
Fig. 2. Phosphorylation of wild-type and mutant nNOSs by a consti-
tutively active form of CaM-K I in vitro. (A) Equal amounts (0.5 lg)
of wild-type (WT) and the mutant nNOS, nNOS S741A (741SA) in E.
coli were separated by 7.5% SDS–PAGE and stained by CBB. The
arrowhead indicates the position of nNOSs. (B) 1 lg of wild-type (WT)
or mutant nNOS, nNOS S741A (741SA) in E. coli was incubated at 30
C with an activated GST/CaM-K I1-293, 100 lM [c-32P]ATP for 30
min in the absence of Ca2þ/CaM. The reaction was stopped by addi-
tion of sample buﬀer. Then, the samples were analyzed by SDS–PAGE
on 7.5% gel and stained by CBB or autoradiography (32P).
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phosphorylation by CaM-K I1-293 and/or wild-type CaM-K I.
Thus, we prepared a rabbit polyclonal antibody (referred to asNP741), raised against the synthetic phosphopeptide: Cys–
Glu–Ala–Val–Lys–Phe-phospho-Ser741–Ala–Lys–Leu–Met–Gly.
The speciﬁcity of NP741 was examined by Western blotting.
NP741 reacted with nNOS phosphorylated by CaM-K I1-293
but not with non-phosphorylated nNOS (Fig. 4A). Phos-
phorylation of nNOS at Ser741 by CaM-K I1-293 was severely
suppressed in the presence of Ca2þ/CaM (Fig. 4B). Fig. 4C
shows that CaM at a 0.6:1 molar ratio to nNOS is required for
half-maximal inhibition apparently. This result indicates that
binding of Ca2þ/CaM to nNOS blocked the phosphorylation
of nNOS at Ser741. The activity of CaM-K I1-293 itself was not
inhibited in the presence of Ca2þ/CaM, using syntide-2 as a
substrate (data not shown). To examine whether CaM-K I1-
293 can phosphorylate nNOS at Ser741 in cells, we analyzed the
phosphorylation of nNOS at Ser741 in HEK-293 cells ex-
pressing nNOS and CaM-K I1-293. Cells were transfected with
the wild-type nNOS and CaM-K I1-293/CaM-KK1-434 or
inactive CaM-K I1-293 (K49A), Lys49 being an essential resi-
due in the ATP binding motif [19]/CaM-KK1-434. We par-
tially puriﬁed nNOS by 20-50-ADP-agarose aﬃnity
chromatography and quantiﬁed the phosphorylation state at
Ser741 and protein expression level. Co-expression of CaM-K
I1-293/CaM-KK1-434 resulted in signiﬁcant enhancement in
the phosphorylation of nNOS at Ser741 relative to cells co-
expressing CaM-K I1-293 (K49A)/CaM-KK1-434 (Fig. 4D).
Also, mutation of Ser741 to an Ala residue abolished CaM-K
I1-293-dependent phosphorylation of nNOS. Therefore, we
next examined whether the phosphorylation at Ser741 could
directly inﬂuence the NOS activity in cells. The enzyme activity
was determined by measuring the conversion of [3H]arginine to
citrulline using a partially puriﬁed nNOS from cell lysates on
20-50-ADP-agarose. Co-transfection of nNOS with CaM-K I1-
293/CaM-KK1-434 resulted in decreased NOS activity in
comparison to the cells co-expressing CaM-K I1-293 (K49A)/
CaM-KK1-434 (Fig. 4D). Cells expressing mutant S741A
nNOS also showed the decrease in NOS activity with CaM-K
I1-293/CaM-KK1-434 but very little in comparison of the cells
expressing wild-type nNOS.
3.4. Phosphorylation of nNOS at Ser741 by CaM-K I in
transfected cells
To examine whether or not phosphorylation of nNOS at
Ser741 by wild-type CaM-K I is observed in cells, nNOS was
co-transfected with CaM-K I/CaM-KK1-434. Then, expressed
nNOSs, partially puriﬁed by ADP-agarose aﬃnity chroma-
tography from lysates, were immunoblotted with NP741 either
with or without 10 lM A23187 stimulation for 3.5 min. In the
absence of stimulation, no phosphorylation was detectable.
Stimulation of the cells with A23187 led to a remarkable in-
crease in the nNOS phosphorylation (Fig. 5A). However,
nNOS was not phosphorylated at Ser741 with A23187 stimu-
lation in the cells expressing CaM- KIIa or HA-CaM-K IV/
CaM-KK1-434. Meanwhile, phosphorylation at Ser847 with
A23187 stimulation was signiﬁcantly enhanced when CaM-
KIIa was expressed. CaM-K II and CaM-K IV are known to
be regulated by autophosphorylation and phosphorylation by
CaM-KK, respectively, and retain partial activity even after
full dissociation of Ca2þ/CaM [22]. The speciﬁcity of Ser741
residue phosphorylation was also examined by immunoblot-
ting in vitro. Recombinant nNOS was phosphorylated by
PKA, PKC, autophosphorylated CaM-K IIa, CaM-KK1-434
phosphorylated CaM-K IV or CaM-KI1-293 and analyzed by
Fig. 5. Determination of kinases that phosphorylate Ser741 of nNOS.
(A) 293 cells expressing nNOS with CaM-K I/CaM-KK1-434 (lane 1),
CaM-K II (lane 2), or HA-CaM-K IV/CaM-KK1-434 (lane 3) were
stimulated with buﬀer alone ()) or 10 lMA23187 for 3.5 min (+). Cell
lysates were subjected to Western blotting with anti-CaM-K I (CaM-K
I), anti-CaM-K II (CaM-K II), or anti-CaM-K IV (CaM-K IV) anti-
bodies. Expressed nNOS was partially puriﬁed from transfected cells
using ADP-agarose chromatography technique (ADP) and subjected
to Western blotting with anti-nNOS (nNOS), NP741 (NP741), or
NP847 (NP847). The data are representatives of at least two inde-
pendent experiments. (B) 0.5 lg each of puriﬁed nNOS was incubated
without any enzyme (lane 1), activated GST/CaM-K I1-293 (lane 2),
autophosphorylated CaM-K II (lane 3), activated CaM-K IV (lane 4),
PKA (lane 5), or PKC (lane 6) with or without [c-32P]ATP in the
absence of CaM. After 7.5% SDS–PAGE, radioactive samples were
stained with CBB and subjected to autoradiography (32P). Non-ra-
dioactive samples were subjected to Western blotting using NP741
(NP741).
Fig. 4. Eﬀects of a constitutively active CaM-K I-induced phosphor-
ylation of nNOS at Ser741 in transfected cells. (A) 0.5 lg each of pu-
riﬁed unphosphorylated nNOS ()) or phosphorylated nNOS (+) by
activated GST/CaM-K I1-293 was separated by 7.5% SDS–PAGE,
transferred onto PVDF membranes, and analyzed by Western blotting
using an anti-nNOS antibody (left panel) or phosphospeciﬁc antibody,
NP741 (right panel). (B) Equal amounts (0.5 lg) of wild-type nNOS in
E. coli were incubated for 30 min at 30 C either in the presence or
absence of Ca2þ/EGTA/CaM/activated GST/CaM-K I1-293 (CaM-K
I1-293/CaM-KK1-434) with 1 mM ATP. The reaction was stopped by
addition of sample buﬀer. Then, the samples were analyzed by 7.5%
SDS–PAGE, transferred onto PVDF membranes, and analyzed by
Western blotting using an anti-nNOS antibody (nNOS) or phospho-
speciﬁc antibody, NP741 (NP741). (C) nNOS (500 nM) was incubated
for 30 min at 30 C with CaM at 0, 10, 30, 100, 300, 1000, or 3000 nM,
1 mM CaCl2, and activated GST/CaM-K I1-293 (CaM-K I1-293/
CaM-KK1-434). Then, the samples were analyzed as in Fig. 2B. (D)
293 cells were transfected with combinations of expression plasmids of
nNOS, nNOS S741A, CaM-K I1-293, CaM-K I1-293 K49E, and
CaM-KK1-434. nNOSs were partially puriﬁed by ADP-agarose and
subjected to Western blotting using an anti-nNOS antibody (lower
panel) or phosphospeciﬁc antibody, NP741 (middle panel). Propor-
tional amounts (1 ll of eluate) were subjected to NOS assay (upper
panel). The meansS.E. of three experiments are shown.
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phosphorylated by CaM-K I1-293 but not those by PKA,
autophosphorylated CaM-K IIa, CaM-KK1-434 phosphory-
lated CaM-K IV. PKC did phosphorylate Ser741 residue, but
only very slightly (Fig. 5B).
Our results support the notion that CaM-K I and CaM-K II
modulate nNOS enzyme activity in cells by adding phosphate
groups to Ser741 and Ser847 residues on the enzyme, respec-
tively. Previously, it has been shown that introduction of a
phosphate at Ser741 of CaM-binding peptide derived from
nNOS prevents binding of CaM [23], consistent with our re-
sults. It was shown that endothelial NOS (eNOS) is phos-
phorylated at Thr495, located in the CaM-binding sequence, by
AMP-activated kinase and by PKC [24–26]. Phosphorylation
of eNOS at this site reduces eNOS catalytic activity in vitro
[24,26,27]. The position of Ser741 is part of a consensus site for
protein phosphorylation (KXSXK) by PKC [28]. Indeed,
phosphorylation of nNOS at Ser741 was induced by PKC in
vitro. Although it was only very slightly compared to that by
CaM-K I1-293 (Fig. 5B), it might be involved in the regulation
of nNOS activity through Ser741 phosphorylation in cells. Al-
though the Thr495 residue found in eNOS is not found in
nNOS, the Ser741 residue in nNOS appears to represent an
essential determinant for transducing the nNOS-CaM inter-
action into stimulation of enzyme activity via its phosphory-
lation. CaM-K II seems to exert its function mainly
postnatally because its gene expression in the brain is evident
T. Song et al. / FEBS Letters 570 (2004) 133–137 137postnatally [29]. In contrast, CaM-K I may be intimately in-
volved in neuronal diﬀerentiation in the brain, since the de-
crease in the expression of CaM-K I with the postnatal age is
observed in most brain neurons [30]. Although a major con-
cern is whether nNOS is actually phosphorylated at Ser741 in
vivo, in the brain, this has not been shown. It needs to be
demonstrated in future work whether nNOS can be phos-
phorylated at Ser741 by CaM-K I in vivo.
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